GANX

Gain Therapeutics, Inc. (NASDAQ:GANX) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bethesda, Maryland. The company went public in March 2021 and focuses on developing novel therapies for rare genetic diseases and neurological disorders caused by protein misfolding. Gain Therapeutics utilizes its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover and develop small molecule treatments that can restore proper protein function in patients with devastating genetic conditions.